BioNTech SE Holds 2025 Annual General Meeting

TL;DR

BioNTech held its 2025 AGM on May 16th, releasing presentation and voting results.

AI Summary

On May 16, 2025, BioNTech SE held its Annual General Meeting (AGM) 2025. The company attached the AGM presentation as Exhibit 99.1 and also provided the voting results from the meeting.

Why It Matters

This filing provides shareholders with information presented at the AGM, including voting results, which are key to corporate governance and understanding shareholder sentiment.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of an annual general meeting and its associated materials, posing no immediate new risks.

Key Players & Entities

• BioNTech SE (company) — Registrant
• May 16, 2025 (date) — Date of AGM

FAQ

From the Filing

0001776985-25-000033.txt : 20250516 0001776985-25-000033.hdr.sgml : 20250516 20250516160940 ACCESSION NUMBER: 0001776985-25-000033 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 35 CONFORMED PERIOD OF REPORT: 20250516 FILED AS OF DATE: 20250516 DATE AS OF CHANGE: 20250516 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioNTech SE CENTRAL INDEX KEY: 0001776985 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: 2M FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39081 FILM NUMBER: 25959258 BUSINESS ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 BUSINESS PHONE: 0049613190840 MAIL ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 6-K 1 form6-k2025agm16may2025.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐ DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On May 16, 2025, BioNTech SE held the Annual General Meeting (“AGM”) 2025. The AGM presentation is attached hereto as Exhibit 99.1. The voting results are attached hereto as Exhibit 99.2. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By: /s/ Jens Holstein By: /s/ Dr. Sierk Poetting Name: Jens Holstein Name: Dr. Sierk Poetting Title: Chief Financial Officer Title: Chief Operating Officer Date: May 16, 2025 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 Annual General Meeting 202 5 Presentation 99.2 Annual General Meeting 202 5 Voting Results EX-99.1 2 a991agmpresentation_engx.htm EX-99.1 a991agmpresentation_engx Annual General Meeting 16 May 2025, 14:00 CET Exhibit 99.1 Management Report 2 1 Operations Development 2024 & Q1 2025 and Outlook 2025 Prof. Dr. Ugur Sahin, Chief Executive Officer & Co-Founder Financial Development 2024 & Q1 2025 and Financial Outlook 2025 Jens Holstein, Chief Financial Officer Operations Development 2024 & Q1 2025 and Outlook 2025 Prof. Dr. Ugur Sahin, CEO & Co-Founder1 4 This Slide Presentation Includes Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech’s expected revenues and net profit/(loss) related to sales of BioNTech’s COVID-19 vaccine, referred to as COMIRNATY where approved for use under full or conditional marketing authorization, in territories controlled by BioNTech’s collaboration partners, particularly for those figures that are derived from preliminary estimates provided by BioNTech’s partners; the rate and degree of market acceptance of BioNTech’s COVID-19 vaccine and, if approved, BioNTech’s investigational medicines; expectations regarding anticipated changes in COVID-19 vaccine demand, including changes to the ordering environment and expected regulatory recommendations t